This is a promotional poster produced and fully funded by Bayer plc for UK healthcare professionals only. Prescribing information and adverse event reporting information for EYLEA® (aflibercept) 2 mg and EYLEA 8 mg can be accessed via the link or QR code located at the bottom of this document.

EYLEA® 8mg
(aflibercept 114.3mg/mL, solution for injection)

EYLEA® (aflibercept) 8 mg real-world evidence

12-month real-world outcomes in treatment-naïve patients with nAMD

University Hospitals Bristol and Weston NHS Foundation Trust

These data are from real patients. Individual results may vary.

Study design:
Retrospective study evaluated visual acuity, central subfield thickness and retinal fluid outcomes in 96 treatment-naïve eyes with nAMD.

All patients received three initial monthly doses of EYLEA 8 mg followed by a T&E protocol up to 12 months.

Patient demographics

Eyes, N	96
Mean age, years	80
Female, %	61.5

Fast and sustained drying with EYLEA 8 mg

Change in CST over time



−85 µm
Mean change in CST from baseline through Month 12

Fluid resolution over time

Proportion of patients with IRF (N=96)



Proportion of patients with SRF (N=96)



Interval extensions
with EYLEA 8 mg

Treatment interval at Month 12



12 ± 3.34 weeks
Mean completed injection interval at Month 12 (N=89*)

Meaningful vision gains
with EYLEA 8 mg

Change in VA over time



+5 ETDRS letters
Mean change in VA from baseline through Month 12 (N=89*)

No serious adverse events were reported in this study with EYLEA 8 mg

Please see the EYLEA 8 mg Summary of Product Characteristics for full details of the safety profile.
*One patient had a myocardial infarction and decided to be observed off treatment, five were switched to faricimab on account of requiring treatment intervals of <q8 (not licensed for EYLEA 8 mg at the time) and one presented with macular atrophy and treatment was stopped. No reported adverse events related to treatment with EYLEA 8 mg.

Abbreviations:
BCVA, best corrected visual acuity; **CST**, central subfield thickness; **ETDRS**, Early Treatment Diabetic Retinopathy Study; **IRF**, intraretinal fluid; **nAMD**, neovascular age-related macular degeneration; **qX**, every X weeks; **SRF**, subretinal fluid; **T&E**, treat-and-extend; **VA**, visual acuity.

Reference:
Bayer UK Data on File_PP-EYL_8mg-GB-0862_January 2026

May 2026 | PP-EYL_8mg-GB-1040

Prescribing information and adverse event reporting information for EYLEA® (aflibercept) is available via the QR code on the right.
Either click **here** or scan the QR code for prescribing information and adverse event reporting information.
For direct access to this prescribing information, please ensure your device's browser settings have automatic PDF download enabled.